Evidence map›Paper›PMID 40168023›Full record

ArticleJAMA network open2025

Psilocybin Dispensaries and Online Health Claims in Canada.

Jenna Matsukubo, Sarah Dickson, Jennifer Xiao, Erik Loewen Friesen, Marco Solmi, Jess G Fiedorowicz, Benedikt Fischer, Daniel T Myran

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution.Canadian journal of public health = Revue canadienne de sante publique · 2026
    Article
  4. Article
  5. Psychedelic therapy and cultural humility.Translational psychiatry · 2026
    Review
  6. Psychedelics: Future Therapeutics in Major Depression?Advances in experimental medicine and biology · 2026
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jenna MatsukuboFaculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Sarah DicksonOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Jennifer XiaoOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Erik Loewen FriesenTemerity Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Marco SolmiOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Jess G FiedorowiczDepartment of Mental Health, The Ottawa Hospital, Ottawa, Ontario, Canada.
Benedikt FischerDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Daniel T MyranOttawa Hospital Research Institute, Ottawa, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: There is growing societal interest in and use of psilocybin. While psilocybin in Canada is illegal outside of clinical trials, there have been anecdotal reports of increasing access via unregulated online purchases and retail dispensaries. Objective: To describe access to and the characteristics of psilocybin dispensaries across Canada and the health claims and warnings made on dispensary websites. Design, Setting, and Participants: This cross-sectional study used systematic web searches and media reports to identify psilocybin dispensaries operating in Canada in May 2024. Data analysis was performed from June 17 to August 29, 2024. Main Outcomes and Measures: Descriptive and geospatial analyses were used to identify the psilocybin dispensary characteristics, product types, and store distribution. Content analysis assessed the nature and frequency of health claims and warnings on websites. Results: As of May 2024, 57 psilocybin dispensaries were identified in Canada (0.18 dispensaries per 100 000 individuals aged ≥15 years) in 15 of Canada's 42 major urban cities (35.7%). Approximately 815 628 (2.6%) of Canadians lived within 1 km of a dispensary. Only 4 of 13 provinces and territories had a dispensary, with most in Ontario and British Columbia. Of the 57 stores, 35 (61.4%) were part of a chain (≥2 stores owned by a single company) and 52 (91.2%) had an online presence. Stores sold a wide variety of products, including dried mushrooms (100.0%), microdosing capsules (97.8%), psilocybin-infused chocolate (91.3%) and gummies (93.4%), and most stores (65.2%) sold products mimicking popular food brands. Among stores with websites, 86.4% claimed mental health benefits of psilocybin (eg, alleviating anxiety). While 86.4% of websites provided health warnings, relevant warnings, such as those about use while driving (9.1%), during pregnancy (13.6%), or in individuals with a history of psychosis, schizophrenia, or bipolar disorder (31.8%) were rare. Conclusions and Relevance: In this study, psilocybin retailers, who were present in over a third of major Canadian cities, made a variety of unverified health claims and lacked warnings of potential harms, suggesting the need for greater regulatory measures to protect the public.

Indexed as

CommerceHallucinogensPsilocybinAdultCanadaCross-Sectional StudiesFemaleHumansInternetHallucinogensPsilocybin

Identifiers

PMID40168023
PMCPMC11962669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.